This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liao, M.-J.
Right arrow Articles by Van Dyke, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liao, M.-J.
Right arrow Articles by Van Dyke, T.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Medline Plus Health Information
*Thymus Cancer

 Previous Article  |  Next Article 

Mol Cell Biol, June 1998, p. 3495-3501, Vol. 18, No. 6
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

No Requirement for V(D)J Recombination in p53-Deficient Thymic Lymphoma

Mai-Jing Liao,1 Xiao-Xiang Zhang,2 Rosina Hill,3 Jingjin Gao,1 Mazin B. Qumsiyeh,2 Warren Nichols,3 and Terry Van Dyke1,*

Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill Medical School, Chapel Hill, North Carolina 275991; Cytogenetics Laboratory, Duke University Medical Center, Durham, North Carolina 277102; and Genetic and Cellular Toxicology, Merck Research Laboratories, West Point, Pennsylvania 194863

Received 21 January 1998/Returned for modification 20 February 1998/Accepted 2 March 1998

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The p53 tumor suppressor is activated in response to a variety of cellular stress signals, although specific in vivo signals that trigger tumor suppression are unknown. In mouse thymocytes, where p53 inactivation leads to tumorigenesis, several observations suggest that V(D)J recombination of T-cell receptor (TCR) loci could provide a DNA damage signal triggering p53-dependent apoptosis and tumor suppression. Inactivation of p53 would allow V(D)J driven mutation of additional cancer genes, facilitating tumorigenesis. Here, we show that mice with a p53 deficiency in thymocytes and unable to carry out V(D)J recombination are not impaired in the development of thymoma. Recombination-activating gene (RAG) deficiencies were introduced into both p53-/- mice and TgTDelta N transgenic mice, a strain in which 100% of the mice develop thymoma due to thymocyte-specific inactivation of p53 by a simian virus 40 T-antigen variant. V(D)J recombination was dispensable for tumorigenesis since thymomas developed with or without the RAG-1 or RAG-2 gene, although some delay was observed. When V(D)J recombination was suppressed by expression of rearranged TCR transgenes, 100% of the TgTDelta N mice developed thymoma, surprisingly with reduced latency. Further introduction of a RAG deficiency into these mice had no impact on the timing or frequency of tumorigenesis. Finally, karyotype and chromosome painting analyses showed no evidence for TCR gene translocations in p53-deficient thymomas, although abundant aneuploidy involving frequent duplication of certain chromosomes was present. Thus, contrary to the current hypothesis, these studies indicate that signals other than V(D)J recombination promote p53 tumor suppression in thymocytes and that the mechanism of tumorigenesis is distinct from TCR translocation oncogene activation.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The p53 tumor suppressor is activated in response to a variety of cellular stress signals, including DNA damage. Its ability to facilitate growth arrest and/or cell death in response to such signals is believed to be the basis for its tumor suppressor function (see references 5, 16, 22, and 27 for reviews). However, specific in vivo signals that trigger tumor suppression have not been identified. Sixty to eighty percent of the spontaneous malignancies in p53-deficient mice are thymic lymphomas (13, 17), indicating that natural thymocyte events signal p53 tumor suppression. The favored hypothesis is that flawed T-cell receptor (TCR) gene recombination events signal p53-dependent elimination of damaged cells (15, 17, 24, 28). p53 inactivation would thus facilitate the survival of cells carrying tumorigenic mutations. This hypothesis is consistent with several observations, including that (i) double-strand DNA breaks (DSBs) trigger p53 responses (29), (ii) p53 is required for DNA damage-induced thymocyte apoptosis (11, 23), (iii) thymic lymphomas induced by p53 deficiency are clonal, indicating that additional tumorigenic events are required (38), and (iv) in scid mice, which accumulate V(D)J breaks, lymphoid malignancies are accelerated by p53 deficiency (15, 28). Since V(D)J translocations are frequently associated with oncogene activation in human and mouse lymphoid tumors, it is reasonable to suspect that these events may be involved in tumorigenesis in the absence of p53-mediated surveillance.

V(D)J recombination affects TCR and immunoglobulin (Ig) DNA rearrangement in developing T and B cells to generate a variety of antigen receptor specificities. Normally this process occurs during specific stages of T- and B-cell differentiation to yield a single productive rearrangement per cell for each polypeptide component of the receptor. The initiating event in V(D)J recombination, the generation of specific DSBs, requires two recombination activating genes (RAGs), RAG-1 and RAG-2 (9, 31). Mice deficient in either of these genes fail to undergo V(D)J recombination and are immunodeficient due to the lack of mature T and B cells (25, 37). Thus, these mice provide an approach for assessing the role of V(D)J recombination in thymomagenesis associated with p53 deficiency. Here we examine the impact of inactivating V(D)J recombination on tumorigenesis by introducing RAG deficiencies and/or rearranged TCR transgenes into mice with a thymocyte p53 deficiency. Additionally, we analyze the chromosomes of p53-deficient thymomas for evidence of TCR translocations and other aberrations.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Mice. RAG-1-/- (C57BL/6J-sv/129), scid/scid (C57BL/6J), TgN(TcrLCMV) (B6D2), and p53-/- (C57BL/6J) mice were from Jackson Laboratory, and RAG-2-/- mice (129, SvEv) were from Taconic Laboratory. TgTDelta N mice (B6D2), previously referred to as TgLST1135, abundantly express the dl1135 simian virus 40 (SV40) large T antigen (T-Ag) in thymocytes under the regulation of the lymphotropic papovavirus transcriptional signals (38). Although low levels of the transgene are also expressed in B cells, only thymic lymphoma develops in these mice (38). The dl1135 protein (referred to here as TDelta N) binds p53 and the pRB family proteins and inactivates p53 in vivo (10, 24). TDelta N is defective in transformation of cultured cells due to a deletion (residues 17 to 27) that inactivates an N-terminal transformation function (32). The TDelta N transgene harbors a deletion in the small t antigen splice donor site and does not express SV40 small t antigen. With the exception of scid mice, PCR assays of tail DNA were used to screen mouse genotypes as previously described (17, 38) or according to Jackson Laboratory [<http://www.jax.org/resources/documents/imr/protocols/TgN(TcrLCMV).html>]. RAG-1 alleles were identified by using two primer pairs: for RAG-1 wild type, RAG-1F (5'-CCA GTA GAT ACC ATT GCG AAG AGG-3') and RAG-1B (5'-CAC GTT CTG TGA ACC ATG CTC TAT C-3'); and for RAG-1 knockout, RAG-1B and Neo-R (5'-CCG CTT CCA TTG CTC AGC GG-3'). PCR conditions were 35 cycles of 30 s at 94°C, 1 min at 59°C, and 1 min at 72°C. RAG-2 alleles were identified by using two primer pairs: for RAG-2 wild type, RAG-2A (5'-GGG AGG ACA CTC ACT TGC CAG TA-3') and RAG-2B (5'-AGT CAG GAG TCT CCA TCT CAC TGA-3'); and for RAG-2 knockout, RAG-2B and Neo-2 (5'-AGG TGA GAT GAC AGG AGA TC-3'). PCR conditions were 35 cycles of 1 min at 94°C, 1 min at 55°C, and 1 min at 72°C. The scid mice were screened by using enzyme-linked immunosorbent assay (ELISA) detection of serum IgM, which is absent in scid mice (14).

To generate TgTDelta N or p53-/-/RAG-/- and TgTDelta N or p53-/-/RAG+/- mice, TgTDelta N or p53-/- mice were bred with RAG-/- (RAG-1 or RAG-2) mice, and F1 offspring were intercrossed. p53-/- mice were bred to C57BL scid/scid mice, and F1 offspring were intercrossed to derive p53-/- scid/scid and p53-/- scid/wt (wild-type) animals. The latter were distinguished from p53-/- wt/wt mice, which are both positive by ELISA, in test breeding with scid/scid mice. If heterozygous at the scid locus, ~50% of the offspring scored negative by ELISA (scid/scid). A similar breeding strategy was used to generate TgTDelta N/scid/scid and TgTdN/scid/wt mice. To generate TgTDelta N/TgTcr/RAG-1-/- and TgTDelta N/TgTcr/RAG-1+/- mice, TgTDelta N/RAG-1-/- mice were crossed to TgN(TcrLCMV) mice, and F1 TgTDelta N/TgTcr/RAG-1+/- mice were further bred with TgTDelta N/RAG-1-/- mice. Animals were sacrificed and necropsied upon showing distressed breathing due to extensive thymic enlargement or were autopsied upon death. Fresh tumor samples were divided and either fixed for immunohistochemistry analysis or used for thymocyte isolation.

FACS analysis. Thymoma cell type was determined by fluorescence-activated cell sorting (FACS) analysis using phycoerythrin (PE)-anti-CD90 (Thy-1.2) and fluorescein isothiocyanate (FITC)-anti-CD45R/B220 antibodies (PharMingen), and thymocyte distribution was determined by using FITC-anti-CD4 and PE-anti-CD8 antibodies (PharMingen), as described previously (18). The thymocyte proliferation index was determined by in vivo labeling with bromodeoxyuridine (BrdU) (Boehringer Mannheim) for 1 h after intraperitoneal injection (0.1 ml/10 g of body weight), isolation of thymocytes as described previously (24, 38), and FACS analysis with FITC-anti-BrdU antibody (Boehringer Mannheim) and propidium iodide staining. The total thymocyte apoptotic index was determined by FACS using a modification of the terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling assay (Cell Death Detection kit) as recommended by Boehringer Mannheim.

Karyotype and fluorescence in situ hybridization analyses. Minced mouse thymoma cells were harvested directly, using routine cytogenetics laboratory procedures for preparation of metaphase chromosomes (41). Karyotypes were determined by standard Giemsa banding techniques (36). Biotinylated mouse whole chromosome paint probes for chromosomes 6, 13, and 14 were used as instructed by the supplier (Oncor, Inc., Gaithersburg, Md.). These probes were obtained from flow-sorted mouse chromosomes and were optimized to hybridize only to target chromosomes. Hybridization to repetitive sequences was suppressed by including excess mouse repetitive DNA. Biotinylated probes were detected by incubation with rabbit antibiotin antibody, biotinylated anti-rabbit antibody, and streptavidin-FITC. Mouse chromosomes were counterstained with propidium iodide. Images of metaphases were captured by a charge-coupled device camera and analyzed with Smartcapture software (Vysis Inc., Downers Grove, Ill.).

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Mice deficient in both RAG and p53 develop thymoma. We introduced RAG-1 or RAG-2 deficiency into mice lacking thymocyte p53 activity by using standard genetic crosses as outlined in Materials and Methods. Since T-cell tumorigenesis in p53-/- mice is not fully penetrant and other complicating tumor types develop, in most experiments we used transgenic mice that express an SV40 T-Ag derivative, TDelta N, specifically in thymocytes (see Materials and Methods). This oncoprotein inactivates p53, and we previously showed that 100% of TgTDelta N mice develop exclusively thymic lymphoma at about 5 months of age (38). Prior to 2 months of age, thymocyte distribution is normal and consists predominantly of CD4 CD8 double-positive (DP) thymocytes (38). From 2 to 5 months, the thymus expands rapidly and consists increasingly of a single Vbeta T-cell class high in cell surface CD3 and CD4 CD8 single positive, double negative, or DP (38). This phenotype is dependent on a functional T-Ag p53-binding domain (40), and T-cell tumors are indistinguishable from those induced by p53 gene inactivation (22a, 38). Furthermore, preneoplastic TgTDelta N thymocytes are defective in irradiation-induced p53-dependent apoptosis (24).

The high frequency and predictability of thymic lymphoma in TgTDelta N mice facilitate quantitative studies on the role of V(D)J recombination. However, in addition we generated p53-/- mice deficient in RAG-2 to control for any unexpected effects of TDelta N. If V(D)J recombination is required for T-cell tumorigenesis in the absence of p53, inactivation of this process would inhibit tumorigenesis. TgTDelta N/RAG-1-/-, TgTDelta N/RAG-2-/-, and p53-/-/RAG-2-/- mice were generated through standard backcrosses, and the timing and frequency of thymoma were measured. All of the mice became ill and were sacrificed and necropsied (Fig. 1A). Thymic lymphoma had developed in the majority of RAG-deficient TgTDelta N mice, although the frequency was somewhat reduced (85% in TgTDelta N/RAG-1-/- mice and 83% in TgTDelta N/RAG-2-/- mice [Table 1]). A few mice developed lymph node tumors or had no obvious neoplasm (a phenotype also observed in mice with RAG deficiency alone [see the legend to Fig. 1]). Thymoma developed in 55% of the p53-/- RAG-2+/- mice (Fig. 1B), a frequency lower than for TgTDelta N mice due to the development of other tumor types (as previously observed). Inactivation of V(D)J recombination did not reduce this frequency, as 67% of p53-/- RAG-2-/- mice developed thymoma (Fig. 1B; Table 1). FACS analysis of three TgTDelta N/RAG-1-/- thymomas showed that cells were CD4 CD8 DP, CD3 negative, and Vbeta negative, consistent with the fact that V(D)J recombination is inactive (data not shown). The high frequency of thymoma in p53 and RAG-deficient mice indicates that V(D)J recombination, and T-cell differentiation in general, is dispensable for T-cell tumorigenesis.


View larger version (23K):
[in this window]
[in a new window]
  		FIG. 1.   Thymoma develops in TgTDelta N and p53-/- mice with altered V(D)J recombination. Survival of mice is plotted against time. Each data point reflects the sacrifice or death of a terminally ill mouse. Due to strain differences, littermates of each cross serve as controls. Mice that did not show overt thymoma are indicated by asterisks. (A) Effect of a RAG-deficient background on the timing and frequency of thymomagenesis in TgTDelta N mice. As with TgTDelta N mice (38), all of the seven TgTDelta N/RAG-1+/- and all of the six TgTDelta N/RAG-2+/- mice developed thymoma. The shorter latency in TgTDelta N/RAG-2+/- mice is most likely caused by background strain effects. Overt thymoma developed in the majority of TgTDelta N/RAG-1-/- (85%, n = 20) and TgTDelta N/RAG-2-/- (83%, n = 12) mice. Three mice of the RAG-1-deficient set and two mice of the RAG-2-deficient set showed no overt thymoma at the time of sacrifice. One TgTDelta N/RAG-1-/- mouse developed a lymph node tumor, and one TgTDelta N/RAG-2-/- mouse had splenomegaly in addition to an enlarged thymus. No neoplasm was detected in the other three mice, a phenotype also observed in mice with only a RAG deficiency (not shown). Six TgTDelta N/RAG-2-/- mice are not included in the survival analysis since their early death precluded assessment of thymoma. Of these, three had lymph node tumors of an undetermined cell type. (B) Effect of RAG-2 deficiency on p53-/- mice. Thymoma developed in 56% of the nine p53-/-/RAG-2+/- mice and in 67% of the nine p53-/-/RAG-2-/- mice. The remaining mice developed other characteristic p53-/- tumors, including sarcoma, testicular tumors, and lymphoma (13, 17).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Summary of effect of V(D)J recombination inactivation on p53-deficient thymoma

Although most RAG-deficient TgTDelta N mice developed thymoma, tumors arose more slowly or with longer latency, based on extended survival (Fig. 1A; Table 1). All of the control TgTDelta N/RAG-1+/- mice developed thymoma with a t50 (time at which half of the animals were sacrificed or died due to overt illness) of 165 days, similar to that previously reported for TgTDelta N mice (38). The t50 for TgTDelta N/RAG-1-/- mice, however, was 238 days. Thymoma developed with reduced latency in control TgTDelta N/RAG-2+/- mice (t50 = 146 days) compared to TgTDelta N mice, most likely due to a background strain effect. Relatively, in TgTDelta N/RAG-2-/- littermates the t50 was again delayed (167 days), albeit to a lesser extent. A similar delay was also observed in p53-/- RAG-2-/- mice (t50 = 180 days) compared to p53-/- RAG-2+/- mice (t50 = 165 days; Fig. 1B, Table 1).

V(D)J recombination is not required for T-cell tumorigenesis. Since RAG-deficient mice harbor fewer thymocytes and are blocked in T-cell development (25, 37), the observed delay and reduced frequency of thymoma may simply reflect a smaller and/or altered target cell population rather than a direct effect of V(D)J recombination. This could cause a dramatic effect, particularly when p53 is inactivated as a result of transgene expression, which may not occur in every cell. To circumvent these complications, T-cell development was rescued in TgTDelta N/RAG-1-/- mice by thymocyte-specific expression of rearranged TCRalpha and TCRbeta transgenes (9). Crosses with mice harboring lymphocytic choriomeningitis virus-specific TCR transgenes [TgN(TcrLCMV)] (33) were carried out as described in Materials and Methods. The effect of TCR transgenes on thymomagenesis in control TgTDelta N/TgTcr/RAG-1+/- mice also served as a test for the role of V(D)J recombination, in that expression of rearranged TCR transgenes alone suppresses (though does not eliminate) V(D)J recombination (42). Surprisingly, tumorigenesis was accelerated in TgTDelta N/TgTcr/RAG-1+/- mice (t50 = 110 days) relative to TgTDelta N/RAG-1+/- littermates (t50 = 165 days) (Fig. 2). Hence, suppressed V(D)J recombination provided no deterrent to tumorigenesis. The reason for accelerated tumor development is unknown, but it could reflect increased target cell numbers or altered thymocyte proliferation. In support of this possibility, young (6-week-old) TgTDelta N/TgTcr/RAG-1+/- mice had an abnormally high percentage of thymocytes in S phase (22.9%), while nontransgenic and TgTDelta N S-phase thymocytes comprised only 8.8 and 8.9%, respectively, of the total population. Total apoptosis levels were unchanged (data not shown).


View larger version (16K):
[in this window]
[in a new window]
  		FIG. 2.   Effect of TCR transgene expression on the timing and frequency of thymomagenesis. TgTDelta N/TgTcr/RAG-1+/- mice (n = 22) developed thymoma with reduced latency compared with TgTDelta N/RAG-1+/- mice (n = 9). RAG-1 deficiency (n = 11) had no further effect. All mice developed thymoma.

To measure the effect of complete inactivation of V(D)J recombination, TgTDelta N/TgTcr/RAG-1+/- mice were further backcrossed to RAG-1-/- mice (see Materials and Methods). Importantly, RAG deficiency had no impact on the timing or frequency of tumorigenesis in TgTDelta N/TgTcr mice (Fig. 2). All TgTDelta N/TgTcr/RAG-1-/- mice developed thymic lymphoma within the same accelerated time frame (t50 = 101 days) as TgTDelta N/TgTcr/RAG-1+/- mice. The predominant cell type in each of three thymomas was CD4 CD8 DP, CD3 positive, and TCRbeta positive. This result shows that the increased latency and slightly reduced frequency of thymoma in RAG-deficient TgTDelta N mice was not due to the absence of V(D)J recombination. Since tumorigenesis was unaffected by complete absence of V(D)J recombination in the presence of T-cell maturation, the recombination process is not required for, nor does it affect the rate of, T-cell tumorigenesis induced by p53 inactivation.

No acceleration of T-cell tumorigenesis in a scid background. Although the foregoing studies show that V(D)J recombination is dispensable for thymoma development, it is possible that the recombination pathway, if present, plays a role that may be compensated for in its absence. This possibility seems unlikely given that the putative compensatory process would not rescue V(D)J recombination and would thus function by a different mechanism. Nonetheless, two approaches were used to test this possibility. In the first approach, tumorigenesis rates were tested in the scid background (8). scid mice are defective in the DNA-dependent protein kinase activity required for rejoining of V(D)J coding DNA ends (12, 43). As a result, scid lymphocytes accumulate V(D)J-associated DSBs. Thus, although the recombination overall is inhibited, the hypothesized signal to p53 would be increased. If such breaks provide secondary cooperating mutations for tumorigenesis in the absence of p53, thymoma development would be accelerated in this background. Indeed, previous studies showed that p53-/-/scid mice died earlier than p53-/- littermates (7, 15, 28). However, because p53 was absent from all cells, these mice developed B-cell, as well as T-cell, lymphoma. In TgTDelta N mice, exclusive analysis of thymoma is possible. Consistent with results for the TgTDelta N/RAG-/- mice, development of thymic lymphoma was not accelerated in TgTDelta N/scid mice (Fig. 3A; Table 1). Instead, tumorigenesis was slightly delayed in these mice (t50 = 210 days) compared to TgTDelta N/scid/wt mice (t50 = 183 days). To determine whether this effect was unique to the transgenic mice, p53-/-/scid crosses were performed (Fig. 3B). Again, thymomagenesis was clearly not accelerated. Although three of five p53-/-/scid/wt mice developed thymoma within the usual time frame (t50 = 183 days), none of the p53-/-/scid/scid mice developed thymoma. Rather, these mice died of other causes with a t50 of 214 days (see the legend to Fig. 3). Because the number of p53-/-/scid/scid mice analyzed was small, this difference may not be statistically significant. However, lack of thymoma acceleration is consistent with what occurs in the TgTDelta N/scid/scid mice. The difference in these experiments compared with those reported previously is not clear but may be attributable to the difference in scid background strains used (see Discussion). The scid-dependent delay observed here in TgTDelta N mice most likely reflects a reduced number of thymocytes as in RAG-deficient mice. Thus, these experiments show no evidence that increased V(D)J DSBs accelerate T-cell lymphoma development in the absence of p53.


View larger version (23K):
[in this window]
[in a new window]
  		FIG. 3.   Tumorigenesis is not accelerated in scid mice. The effect of the scid mutation on the timing and frequency of thymomagenesis in TgTDelta N and p53-/- mice was measured as described in the legend to Fig. 1. (A) TgTDelta N/scid/scid mice (n = 29) developed thymoma with increased latency compared with their TgTDelta N/scid/wt littermates (n = 15); 93% of the TgTDelta N/scid/wt mice and 62% of the TgTDelta N/scid/scid mice developed thymoma. One TgTDelta N/scid/wt mouse and four TgTDelta N/scid/scid mice developed splenomegaly. No neoplasm was detected in seven TgTDelta N/scid/scid mice. (B) Thymoma developed in 60% of the five p53-/-/scid/wt mice, but in none of the five p53-/-/scid/scid mice. The nine control scid/scid mice did not develop thymoma, and most remained alive for the duration of the study. Mice without overt thymoma are indicated by asterisks.

Chromosome analysis of p53-deficient thymomas. As another test for participation of V(D)J recombination in p53-deficient thymic lymphoma, chromosomes of TgTDelta N thymomas were analyzed for evidence of translocations involving TCR loci. If flawed recombination events provide the signal for p53 tumor suppression, these events should contribute to tumorigenesis in the absence of p53 and would be identifiable in tumor cells. This is a reasonable expectation since tumorigenic translocations involving TCR or Ig genes occur in several human T- and B-cell neoplasms (20, 30, 35). Furthermore, TCR translocations are readily observed with increased frequency in ataxia telangiectasia (AT) lymphoid malignancies (20, 39) and in thymomas induced by ATM (AT mutated) deficiency in mice (4, 45). Evidence suggests that ATM has a role in some p53 DNA damage-induced checkpoints (19).

Karyotypes of nine TgTDelta N and three p53-/- terminal thymomas were analyzed (Table 2). Only three tumors harbored translocations in the majority of cells analyzed, and none of these involved the TCR-bearing chromosomes 6, 13, and 14. In contrast, aneuploidy, including abundant trisomy and some tetrasomy, was frequently observed. Although any of the 20 chromosomes could be affected, trisomy of chromosome 1, 4, 5, or 15 was frequently present (Table 2). Such specificity in chromosome aberrations may indicate the participation of oncogene amplification in thymoma development. Although these data are not sufficient to address the role of any given oncogene, several genes, including some (c-myc [2, 6], lck [1], and scl/tal1 [3, 21]) known to play a role in T-cell tumorigenesis, are present on the selected chromosomes (Table 3).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   Chromosome aberrations in p53-deficient thymic lymphomasa

                              
View this table:
[in this window]
[in a new window]
  		TABLE 3.   Proto-oncogenes encoded by tumor-specific trisomiesa

To be sure that karyotype analysis did not overlook TCR translocations not visibly detectable, we further analyzed tumors by chromosome painting. Metaphase spreads from seven TgTDelta N, one TgTDelta N/RAG-1+/-, and two TgTDelta N/RAG-1-/- tumors were painted with whole-chromosome probes for chromosomes 6, 13, and 14. None of these tumors showed evidence of TCR translocation, while a control ATM-deficient tumor showed a t(14;14) translocation in all cells examined (Fig. 4; Table 4). Together with the genetic evidence described above, these studies indicate that V(D)J recombination does not participate significantly in p53-deficient thymomagenesis. The chromosome analysis also suggests that the mechanism for thymic lymphoma induction may be different for p53 deficiency than for ATM deficiency, in which case these factors function in distinct pathways in thymocyte tumor suppression. This notion is supported by the observation that thymoma development is more rapid in ATM-/-/p53-/- mice than in mice harboring either single deficiency (44).


View larger version (121K):
[in this window]
[in a new window]
  		FIG. 4.   p53-deficient thymomas do not contain TCR translocations. Metaphase spreads were hybridized with paint probes as indicated in Materials and Methods. (A) Chromosome 14 probe showing painting of one large chromosome illustrating t(14;14) in an ATM-/- control thymoma. (B) The same metaphase using only a filter for propidium iodide. (C) Trisomy 14 in a TgTDelta N-3 thymoma, representative of trisomy observed in several samples (Table 4). (D) Representative disomy 14 in a TgTDelta N-1 thymoma. Note that the painting probes do not paint the entire chromosome because of suppression by total mouse repetitive sequences to maintain specificity (34).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 4.   Painting analysis of TCR chromosomesa

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Although previous data are consistent with the hypothesis that TCR gene recombination could be involved in p53-deficient T-cell tumorigenesis, studies presented here indicate that this process is not required. Inactivation of V(D)J recombination using RAG-deficient mice did not inhibit T-cell tumorigenesis predisposed by p53 deficiency. This was most evident in TgTDelta N/RAG-1-/- mice in which T-cell maturation was rescued by expression of rearranged TCRalpha and -beta transgenes. In that case, neither the timing nor the frequency of tumorigenesis was affected by the absence of V(D)J recombination relative to controls. Interestingly, expression of rearranged TCR genes in TgTDelta N mice accelerated T-cell tumorigenesis. Although initially surprising, the high S-phase thymocyte population associated with TCR transgene expression could account for this result. Neither p53-/- nor TgTDelta N thymocytes proliferate above normal levels prior to overt thymoma, while thymoma cells have a high proliferative index (22a). Thus, proliferation of TCR transgene-expressing thymocytes may overcome the need for genetic events that stimulate this step in tumorigenesis. Regardless of the reason for acceleration of these tumors, they do not require V(D)J recombination. Thymoma developed in 100% of TgTDelta N/TgTcr mice, even though allelic exclusion substantially suppresses recombination. Moreover, further inactivation of V(D)J recombination by RAG deficiency had no effect on thymoma development. Recent studies by Nacht and Jacks (27) also concluded that V(D)J recombination was not required for p53 deficiency-induced thymoma. Their studies showed that a RAG deficiency in the p53-/- background did not significantly alter tumor development in p53-/- mice.

In the absence of TCR transgene expression, RAG deficiency alone caused a delay in thymoma development, although these tumors occurred with a high frequency. This effect was most dramatic in TgTDelta N/RAG-1-/- mice, which lived 44% longer than controls. The effect was not as dramatic in TgTDelta N/RAG-2-/- or p53-/-/RAG-2-/- mice, although these mice lived longer (14 and 9%, respectively) than controls as well. In the study by Nacht and Jacks (27), a RAG-1 deficiency did not significantly alter the survival time of p53-/- mice. Thus, the delay we observed in TgTDelta N/RAG-1-/- mice may be specific to the dependence on transgene expression for p53 inactivation. The altered thymocyte population caused by RAG deficiency could affect the percentage of cells expressing TDelta N. While we know that the majority of TgTDelta N thymocytes express TDelta N, we did not examine the TgTDelta N/RAG-1-/- thymocytes for TDelta N expression. Our experiments using TCR transgenic mice support the conclusion that the delay in thymoma development was caused by the altered and/or reduced RAG-deficient thymocyte population. Expression of rearranged TCR transgenes in RAG-deficient mice is known to rescue the defect in mature T-cell production (9), and in this background a RAG-specific delay in tumorigenesis is not observed. Since it is unlikely that expression of the TCR transgenes also completely alters the mechanism of thymomagenesis, we conclude that inactivation of V(D)J recombination has no impact on the development of thymoma induced by p53 deficiency.

Our studies with scid mice also support the notion that V(D)J DSBs associated with an inability to rejoin coding ends do not promote thymoma. In the homozygous scid background, we observed no acceleration of thymoma with either TgTDelta N or p53-/- mice. This result was surprising since previous reports showed that p53-/- scid/scid mice developed accelerated lymphoid malignancies compared to p53-/- mice (15, 28). In those studies, most mice (60 to 88%) developed predominantly B-cell lymphoma, although some T-cell lymphoma was observed. Thus, a high frequency of accelerated thymoma was not specifically observed. TgTDelta N mice develop only thymoma; survival of TgTDelta N mice homozygous at the scid locus is extended by 15%, and 62% of the mice develop thymoma. However, the difference in our study compared to previous reports was not specific to p53 inactivation by TDelta N, since the p53-/- scid/scid mice in our study also showed no acceleration of death due to lymphoma. A plausible explanation for the difference between studies is that the scid mutation was in different genetic backgrounds---C.B-17 in previous studies and C57BL/6J here. Nacht et al. showed that the genetic background significantly affected the extent of lymphoma acceleration in p53-/- scid/scid mice relative to controls, with the effect being more dramatic in a 129/Sv-C57BL6-C.B-17 background than in a C57BL6-C.B-17 background (28). The p53-/- scid/scid mice generated in our study were entirely C57BL6, while the TgTDelta N scid/scid mice were C57BL6-DBA. In addition to having the defect in V(D)J recombination, scid mice are defective in general DNA repair mechanisms (8, 43). In fact, the previous reports established that a DNA damage-inducible p53 checkpoint is intact in scid mice (7, 15, 28). Thus, it is possible that the acceleration of lymphoma previously observed reflects the absence of a general DNA damage checkpoint not specific to V(D)J recombination and that the level of damage, repair, or p53-independent checkpoint functions varies in distinct genetic backgrounds.

In this study, we also show that TCR translocations are not apparent in thymomas induced by a p53 deficiency. The chromosome painting analysis was performed blind, and the ATM-/- thymoma was readily characterized as harboring a TCR translocation. None of the other thymomas analyzed (all of which were induced by p53 deficiency) carried a TCR translocation detectable by this method. Chromosome painting is not sensitive enough to detect small deletions or insertions (34), and so we cannot rule out that aberrant rearrangement of TCR loci occurred at some level. However, this method readily detected a high frequency of TCR translocations in thymomas from ATM-/- mice (4). Thus, if TCR aberrations are involved in p53-deficient thymoma, the mechanism appears to be distinct from that caused by an ATM deficiency. Together with the genetic data described above, the chromosome analysis indicates that V(D)J recombination does not play a substantial role in thymomagenesis induced by p53 deficiency.

The observation that V(D)J recombination is not required for p53-deficient thymomagenesis is surprising since DNA damage-induced apoptosis of thymocytes has been considered the basis for tumor suppression in this cell type. Given that a high frequency of p53-/- mice and all TgTDelta N mice spontaneously develop thymic lymphoma, thymocytes clearly need p53 tumor suppression for normal homeostasis. Perhaps T cells are susceptible to more general forms of DNA damage at some developmental stages. Alternatively, it is possible that the natural p53 signal does not involve DNA damage in these cells. Many aberrant conditions, including cell growth disruption, oxidative stress, and altered metabolic pools, induce p53 function in other cell types (see reference 22 for a review). The challenge now is to determine which, if any, of these conditions contributes to p53 tumor suppression in T cells. Although p53 is not required for apoptosis associated with clonal deletion of T cells (11, 23, 24), it could be required for apoptosis induced by an as yet unknown stimulus. Alternatively, p53 tumor suppression in thymocytes may involve a growth arrest checkpoint function in addition to, or instead of, apoptosis. For example, the consistent presence of aneuploidy in p53-deficient thymoma may indicate that loss of p53 checkpoint regulation leading to genetic instability has a key role in this tumor type.

    ACKNOWLEDGMENTS

We acknowledge Anthony Wynshaw-Boris for providing us with ATM+/- mice. We thank Tyler Jacks for communicating data prior to publication and Larry Arnold for help with the flow cytometry. We also thank Linda Greene for assistance in the preparation of the manuscript and Chaoying Yin for reading of the manuscript.

This research is supported by NIH grant CA65773 to T.V.D.

    FOOTNOTES

* Corresponding author. Mailing address: Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill Medical School, Chapel Hill, NC 27599. Phone: (919) 962-2145. Fax: (919) 962-4296. E-mail: tvdlab{at}med.unc.edu.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

1. Abraham, K. M., S. D. Levin, J. D. Marth, K. A. Forbush, and R. M. Perlmutter. 1991. Thymic tumorigenesis induced by overexpression of p56lck. Proc. Natl. Acad. Sci. USA 88:3977-3981[Abstract/Free Full Text].
2. Adams, J. M., and S. Cory. 1991. Transgenic models for haemopoietic malignancies. Biochim. Biophys. Acta Rev. Cancer 1072:9-31[Medline].
3. Aplan, P. D., et al. 1997. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J. 16:2408-2419[Medline].
4. Barlow, C., S. Hirotsune, R. Paylor, M. Liyanage, M. Eckhaus, F. Collins, Y. Shiloh, J. N. Crawley, T. Ried, D. Tagle, and A. Wynshaw-Boris. 1996. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86:159-171[Medline].
5. Bates, S., and K. H. Vousden. 1996. p53 in signaling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev. 6:12-19[Medline].
6. Berns, A. 1991. Tumorigenesis in transgenic mice: identification and characterization of synergizing oncogenes. J. Cell. Biochem. 47:130-135[Medline].
7. Bogue, M. A., C. Zhu, E. Aguilar-Cordova, L. A. Donehower, and D. B. Roth. 1996. p53 is required for both radiation-induced differentiation and rescue of V(D)J rearrangement in scid mouse thymocytes. Genes Dev. 10:553-565[Abstract/Free Full Text].
8. Bosma, M., and A. Carroll. 1991. The SCID mouse mutant: definition, characterization, and potential uses. Annu. Rev. Immunol. 9:323-350[Medline].
9. Chen, J., Y. Shinkai, F. Young, and F. Alt. 1994. Probing immune functions in RAG-deficient mice. Curr. Biol. 6:313-319.
10. Chen, J., G. Tobin, J. M. Pipas, and T. A. Van Dyke. 1992. T antigen mutant activities in transgenic mice: roles of p53 and pRB-binding in tumorigenesis of the choroid plexus. Oncogene 7:1167-1175[Medline].
11. Clarke, A. R., C. A. Purdie, D. J. Harrison, R. G. Morris, C. C. Bird, M. L. Hooper, and A. H. Wyllie. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852[Medline].
12. Danska, J. S., and C. J. Guidos. 1997. Essential and perilous: V(D)J recombination and DNA damage checkpoints in lymphocyte precursors. Semin. Immunol. 9:199-206[Medline].
13. Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. J. Montgomery, J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221[Medline].
14. Froidevaux, S., and F. Loor. 1991. A quick procedure for identifying doubly homozygous immunodeficient scid beige mice. J. Immunol. Methods 137:275-279[Medline].
15. Guidos, C. J., C. J. Williams, I. Grandal, G. Knowles, M. T. F. Guang, and F. S. Danska. 1996. V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Genes Dev. 10:2038-2054[Abstract/Free Full Text].
16. Hansen, R., and M. Oren. 1997. p53; from inductive signal to cellular effect. Curr. Opin. Genet. Dev. 7:46-51[Medline].
17. Jacks, T., L. Remington, B. Williams, E. Schmitt, S. Halachmi, R. Bronson, and R. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1-7[Medline].
18. Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311[Abstract/Free Full Text].
19. Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. J. Fornace. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597[Medline].
20. Kirsch, I. R., and F. Lista. 1997. Lymphocyte-specific genomic instability and risk of lymphoid malignancy. Semin. Immunol. 9:207-215[Medline].
21. Larson, R. C., et al. 1996. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J. 15:1021-1027[Medline].
22. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331[Medline].
22a. Liao, M.-J., et al. Unpublished data.
23. Lowe, S. W., E. M. Schmitt, S. W. Smith, B. A. Osborne, and T. Jacks. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849[Medline].
24. McCarthy, S. A., H. S. Symonds, and T. Van Dyke. 1994. Regulation of apoptosis in transgenic mice by SV40 T antigen-mediated inactivation of p53. Proc. Natl. Acad. Sci. USA 91:3979-3983[Abstract/Free Full Text].
25. Mombaerts, P., J. Iacomini, R. S. Johnson, K. Herrup, S. Tonegawa, and V. Papaioannou. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869-877[Medline].
26. Morgan, S. E., and M. B. Kastan. 1997. p53 and ATM: cell cycle, cell death, and cancer. Adv. Cancer Res. 71:1-25[Medline].
27. Nacht, M., and T. Jacks. 1998. VDJ recombination is not required for the development of lymphoma in p53-deficient mice. Cell Growth Differ. 9:131-138[Abstract].
28. Nacht, M., A. Strasser, Y. Chan, A. W. Harris, M. Schlissel, R. T. Bronson, and T. Jacks. 1996. Mutations in the p53 and scid genes cooperate in tumorigenesis. Genes Dev. 10:2055-2065[Abstract/Free Full Text].
29. Nelson, W., and M. Kastan. 1994. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14:1815-1823[Abstract/Free Full Text].
30. Nowell, P. C. 1997. Genetic alterations in leukemias and lymphomas: impressive progress and continuing complexity. Cancer Genet. Cytogenet. 94:13-19[Medline].
31. Oettinger, M. 1992. Activation of V(D)J recombination by RAG1 and RAG2. Trends Genet. 8:413-416[Medline].
32. Pipas, J. M., K. W. Peden, and D. Nathans. 1983. Mutational analysis of simian virus 40 T antigen: isolation and characterization of mutants with deletions in the T-antigen gene. Mol. Cell. Biol. 3:203-213[Abstract/Free Full Text].
33. Pircher, H., K. Burki, R. Lang, H. Hengartner, and R. M. Zinkernagel. 1989. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342:559-561[Medline].
34. Qumsiyeh, M. B., and J. A. Peppers. 1996. Sensitivity and specificity of whole chromosome paint (WCP) probes are correlated with size of translocated segment. Am. J. Med. Genet. 65:173[Medline].
35. Rabbitts, T. H. 1994. Chromosomal translocations in human cancer. Nature 372:143-149[Medline].
36. Seabright, M. 1971. A rapid banding technique for human chromosomes. Lancet ii:971-972.
37. Shinkai, Y., G. Rathbun, K. Lam, E. Oltz, V. Stewart, M. Mendelsohn, J. Charron, M. Datta, F. Young, A. Stall, and F. Alt. 1992. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68:855-867[Medline].
38. Symonds, H. S., S. A. McCarthy, J. Chen, J. M. Pipas, and T. Van Dyke. 1993. Use of transgenic mice reveals cell-specific transformation by a simian virus 40 T-antigen amino-terminal mutant. Mol. Cell. Biol. 13:3255-3265[Abstract/Free Full Text].
39. Taylor, A. M. R., J. A. Metcalfe, J. Thick, and Y.-F. Mak. 1996. Leukemia and lymphoma in ataxia telangiectasia. Blood 87:423-438[Abstract/Free Full Text].
40. Van Dyke, T. A. 1994. Analysis of viral-host protein interactions and tumorigenesis in transgenic mice. Semin. Cancer Biol. 5:106.1-106.14.
41. Verma, R. S., and A. Babu. 1989. In Human chromosomes: manual of basic techniques. Pergamon Press, New York, N.Y.
42. von Boehmer, H. 1990. Developmental biology of T cells in T cell-receptor transgenic mice. Annu. Rev. Immunol. 8:531-556[Medline].
43. Weaver, D. T. 1995. What to do at an end: DNA double-strand-break repair. Trends Genet. 11:388-392[Medline].
44. Westphal, C. H., S. Rowan, C. Schmaltz, A. Elson, D. E. Fisher, and P. Leder. 1997. Atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nat. Genet. 16:396-401.
45. Xu, Y., T. Ashley, E. E. Brainerd, R. T. Bronson, M. S. Meyn, and D. Baltimore. 1996. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10:2411-2422[Abstract/Free Full Text].

Mol Cell Biol, June 1998, p. 3495-3501, Vol. 18, No. 6
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Giblin, W., Chatterji, M., Westfield, G., Masud, T., Theisen, B., Cheng, H.-L., DeVido, J., Alt, F. W., Ferguson, D. O., Schatz, D. G., Sekiguchi, J. (2009). Leaky severe combined immunodeficiency and aberrant DNA rearrangements due to a hypomorphic RAG1 mutation. Blood 113: 2965-2975 [Abstract] [Full Text]  
  • Xu, M., Yu, Q., Subrahmanyam, R., Difilippantonio, M. J., Ried, T., Sen, J. M. (2008). {beta}-Catenin Expression Results in p53-Independent DNA Damage and Oncogene-Induced Senescence in Prelymphomagenic Thymocytes In Vivo. Mol. Cell. Biol. 28: 1713-1723 [Abstract] [Full Text]  
  • Bassing, C. H., Ranganath, S., Murphy, M., Savic, V., Gleason, M., Alt, F. W. (2008). Aberrant V(D)J recombination is not required for rapid development of H2ax/p53-deficient thymic lymphomas with clonal translocations. Blood 111: 2163-2169 [Abstract] [Full Text]  
  • dos Santos, N. R., Rickman, D. S., de Reynies, A., Cormier, F., Williame, M., Blanchard, C., Stern, M.-H., Ghysdael, J. (2007). Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia. Blood 109: 3972-3981 [Abstract] [Full Text]  
  • Morales, J. C., Franco, S., Murphy, M. M., Bassing, C. H., Mills, K. D., Adams, M. M., Walsh, N. C., Manis, J. P., Rassidakis, G. Z., Alt, F. W., Carpenter, P. B. (2006). 53BP1 and p53 synergize to suppress genomic instability and lymphomagenesis. Proc. Natl. Acad. Sci. USA 103: 3310-3315 [Abstract] [Full Text]  
  • Ward, I. M., Difilippantonio, S., Minn, K., Mueller, M. D., Molina, J. R., Yu, X., Frisk, C. S., Ried, T., Nussenzweig, A., Chen, J. (2005). 53BP1 Cooperates with p53 and Functions as a Haploinsufficient Tumor Suppressor in Mice. Mol. Cell. Biol. 25: 10079-10086 [Abstract] [Full Text]  
  • Winrow, C. J., Pankratz, D. G., Vibat, C. R. T., Bowen, T.J., Callahan, M. A., Warren, A. J., Hilbush, B. S., Wynshaw-Boris, A., Hasel, K. W., Weaver, Z., Lockhart, D. J., Barlow, C. (2005). Aberrant recombination involving the granzyme locus occurs in Atm-/- T-cell lymphomas. Hum Mol Genet 14: 2671-2684 [Abstract] [Full Text]  
  • Sakata, J., Inoue, J., Ohi, H., Kosugi-Okano, H., Mishima, Y., Hatakeyama, K., Niwa, O., Kominami, R. (2004). Involvement of V(D)J recombinase in the generation of intragenic deletions in the Rit1/Bcl11b tumor suppressor gene in {gamma}-ray-induced thymic lymphomas and in normal thymus of the mouse. Carcinogenesis 25: 1069-1075 [Abstract] [Full Text]  
  • Rooney, S., Sekiguchi, J., Whitlow, S., Eckersdorff, M., Manis, J. P., Lee, C., Ferguson, D. O., Alt, F. W. (2004). Artemis and p53 cooperate to suppress oncogenic N-myc amplification in progenitor B cells. Proc. Natl. Acad. Sci. USA 101: 2410-2415 [Abstract] [Full Text]  
  • Engel, I., Murre, C. (2002). Disruption of pre-TCR expression accelerates lymphomagenesis in E2A-deficient mice. Proc. Natl. Acad. Sci. USA 99: 11322-11327 [Abstract] [Full Text]  
  • Difilippantonio, M. J., Petersen, S., Chen, H. T., Johnson, R., Jasin, M., Kanaar, R., Ried, T., Nussenzweig, A. (2002). Evidence for Replicative Repair of DNA Double-Strand Breaks Leading to Oncogenic Translocation and Gene Amplification. JEM 196: 469-480 [Abstract] [Full Text]  
  • Engel, I., Johns, C., Bain, G., Rivera, R. R., Murre, C. (2001). Early Thymocyte Development Is Regulated by Modulation of E2a Protein Activity. JEM 194: 733-746 [Abstract] [Full Text]  
  • Lu, X., Magrane, G., Yin, C., Louis, D. N., Gray, J., Van Dyke, T. (2001). Selective Inactivation of p53 Facilitates Mouse Epithelial Tumor Progression without Chromosomal Instability. Mol. Cell. Biol. 21: 6017-6030 [Abstract] [Full Text]  
  • Chervinsky, D. S., Lam, D. H., Melman, M. P., Gross, K. W., Aplan, P. D. (2001). scid Thymocytes with TCR{beta} Gene Rearrangements Are Targets for the Oncogenic Effect of SCL and LMO1 Transgenes. Cancer Res. 61: 6382-6387 [Abstract] [Full Text]  
  • Allman, D., Karnell, F. G., Punt, J. A., Bakkour, S., Xu, L., Myung, P., Koretzky, G. A., Pui, J. C., Aster, J. C., Pear, W. S. (2001). Separation of Notch1 Promoted Lineage Commitment and Expansion/Transformation in Developing T Cells. JEM 194: 99-106 [Abstract] [Full Text]  
  • Williams, C. J., Grandal, I., Vesprini, D. J., Wojtyra, U., Danska, J. S., Guidos, C. J. (2001). Irradiation Promotes V(D)J Joining and RAG-Dependent Neoplastic Transformation in SCID T-Cell Precursors. Mol. Cell. Biol. 21: 400-413 [Abstract] [Full Text]  
  • Wen, R., Wang, D., McKay, C., Bunting, K. D., Marine, J.-C., Vanin, E. F., Zambetti, G. P., Korsmeyer, S. J., Ihle, J. N., Cleveland, J. L. (2001). Jak3 Selectively Regulates Bax and Bcl-2 Expression To Promote T-Cell Development. Mol. Cell. Biol. 21: 678-689 [Abstract] [Full Text]  
  • Poetschke, H. L., Klug, D. B., Perkins, S. N., Wang, T. T.Y., Richie, E. R., Hursting, S. D. (2000). Effects of calorie restriction on thymocyte growth, death and maturation. Carcinogenesis 21: 1959-1964 [Abstract] [Full Text]  
  • Gomez, G., Clarkin, K. Z., Kraig, E., Infante, A. J., Richie, E. R. (2000). TCR V{beta} repertoire restriction and lack of CDR3 conservation implicate TCR-superantigen interactions in promoting the clonal evolution of murine thymic lymphomas. Int Immunol 12: 263-270 [Abstract] [Full Text]  
  • Vanasse, G. J., Concannon, P., Willerford, D. M. (1999). Regulated Genomic Instability and Neoplasia in the Lymphoid Lineage. Blood 94: 3997-4010 [Full Text]  
  • Liao, M.-J., Van Dyke, T. (1999). Critical role for Atm in suppressing V(D)J recombination-driven thymic lymphoma. Genes Dev. 13: 1246-1250 [Abstract] [Full Text]  
  • Kamijo, T., Bodner, S., van de Kamp, E., Randle, D. H., Sherr, C. J. (1999). Tumor Spectrum in ARF-deficient Mice. Cancer Res. 59: 2217-2222 [Abstract] [Full Text]  
  • Liao, M.-J., Yin, C., Barlow, C., Wynshaw-Boris, A., van Dyke, T. (1999). Atm Is Dispensable for p53 Apoptosis and Tumor Suppression Triggered by Cell Cycle Dysfunction. Mol. Cell. Biol. 19: 3095-3102 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liao, M.-J.
Right arrow Articles by Van Dyke, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liao, M.-J.
Right arrow Articles by Van Dyke, T.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Medline Plus Health Information
*Thymus Cancer

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»